AbbVie Inc AbbVie (NYSE: ABBV) to Ends its Collaboration with BioArctic AbbVie Inc. (NYSE: ABBV) has decided to end its partnership with BioArctic regarding the portfolio of alpha-synuclein antibodies, including ABBV-0805. BioArctic and AbbVie have joined hands since 2016 regarding the
AbbVie Inc AbbVie (NYSE: ABBV) and Gedeon Richter Confirm Partnership AbbVie Inc. (NYSE: ABBV) confirmed that it has inked a new co-development and license agreement with Gedeon Richter Plc. ('Richter') to research, develop, and market novel dopamine receptor modulators for
